Literature DB >> 12419962

Adhesive defect in extracellular matrix tenascin-X-null fibroblasts: a possible mechanism of tumor invasion.

Takeharu Minamitani1, Hiroyoshi Ariga, Ken-Ichi Matsumoto.   

Abstract

Extracellular matrix tenascin-X (TNX)-null mice, generated by disruption of the Tnx gene, display augmented invasion and metastasis of B16-BL6 melanoma tumor cells due to increased activities of matrix metalloproteinase (MMP)-2 and MMP-9. In this study, we investigated cell-matrix and cell-cell adhesions using TNX-null fibroblasts and wild-type fibroblasts. TNX-null fibroblasts exhibited a decreased attachment to fibronectin compared with that of wild-type fibroblasts. B16 melanoma cells were cocultured with wild-type or TNX-null fibroblasts, and the adhesion of B16 melanoma to the fibroblasts was assessed. B16 melanoma cells on wild-type fibroblasts proliferated and spread out in a horizontal direction, whereas those on TNX-null fibroblasts overlapped each other rather than migrating horizontally. These overlapping B16 melanoma cells on TNX-null fibroblasts peeled off faster than those on wild-type fibroblasts. To determine whether the decreased cell-matrix and cell-cell adhesions on TNX-null fibroblasts were due to increased MMP activity, the activities of MMPs in wild-type and TNX-null fibroblasts were compared by gelatinolytic assays. The analysis of MMPs from conditioned media demonstrated that almost the same levels of MMP activities were detected between wild-type and TNX-null fibroblasts. However, contrary to our expectations the activities of MMPs from conditioned media of B16 melanoma cells cocultured on TNX-null fibroblasts were rather reduced than those of B16 melanoma cells cocultured on wild-type. We concluded that the absence of TNX in the extracellular environment might play an important role in enhancement of the detachment of B16 melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419962     DOI: 10.1248/bpb.25.1472

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses.

Authors:  Eric M Blalock; James W Geddes; Kuey Chu Chen; Nada M Porter; William R Markesbery; Philip W Landfield
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

2.  Exome-wide analyses identify low-frequency variant in CYP26B1 and additional coding variants associated with esophageal squamous cell carcinoma.

Authors:  Jiang Chang; Rong Zhong; Jianbo Tian; Jiaoyuan Li; Kan Zhai; Juntao Ke; Jiao Lou; Wei Chen; Beibei Zhu; Na Shen; Yi Zhang; Ying Zhu; Yajie Gong; Yang Yang; Danyi Zou; Xiating Peng; Zhi Zhang; Xuemei Zhang; Kun Huang; Tangchun Wu; Chen Wu; Xiaoping Miao; Dongxin Lin
Journal:  Nat Genet       Date:  2018-01-29       Impact factor: 38.330

3.  Xq25 and Xq26 identify the common minimal deletion region in malignant gastroenteropancreatic endocrine carcinomas.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Silvia Pizzi; Tiziana D'Adda; Guido Rindi; Cesare Bordi
Journal:  Virchows Arch       Date:  2005-10-22       Impact factor: 4.064

4.  Rat mammary extracellular matrix composition and response to ibuprofen treatment during postpartum involution by differential GeLC-MS/MS analysis.

Authors:  Jenean H O'Brien; Lauren A Vanderlinden; Pepper J Schedin; Kirk C Hansen
Journal:  J Proteome Res       Date:  2012-08-30       Impact factor: 4.466

5.  Tenascin-X in amniotic fluid and reproductive tissues of pregnancies complicated by infection and preterm prelabor rupture of membranes†.

Authors:  Kara M Rood; Catalin S Buhimschi; Guomao Zhao; Emily A Oliver; Taryn Summerfield; Mert Ozan Bahtiyar; Irina A Buhimschi
Journal:  Biol Reprod       Date:  2019-03-01       Impact factor: 4.285

6.  Secretome Identifies Tenascin-X as a Potent Marker of Ovarian Cancer.

Authors:  Marianne Kramer; Sandra Pierredon; Pascale Ribaux; Jean-Christophe Tille; Patrick Petignat; Marie Cohen
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.